Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest ...

TAMPA, Fla. and LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today ...

ISLAMABAD: The Higher Education Commission (HEC) on Friday said it has initiated a project to revamp its degree attestation system by integrating cutting-edge blockchain technology. “This pivotal ...

WASHINGTON, Dec 3 (Reuters) - U.S. import prices were unexpectedly unchanged in September as high costs for consumer goods, excluding motor vehicles, were offset by cheaper energy products. The flat ...

ISLAMABAD: Renowned academician and public health specialist Prof Dr Ziaul Haq assumed the office of executive director (ED) of the Higher Education Commission (HEC) on Friday. Before joining the HEC, ...

Tuesday is when we’re supposed to learn more about how imports and exports have been faring from the Bureau of Labor Statistics, though the 43-day government shutdown may still delay that data release ...

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the publication of a ...

Bain Capital agreed to sell its data centers in China to Shenzhen Dongyangguang Industry Co. in a transaction valued at about $4 billion. Shenzhen Dongyangguang, the parent of Shanghai-listed ...

As AI workloads scale and data center operations become increasingly complex, it is critical to keep the infrastructure up and running. Total Cost of Ownership (TCO) is a key metric that includes not ...

– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg ...

Revolution Medicines has secured a potential funding infusion of up to $2 billion from Royalty Pharma in return for a slice of the profits if Revolution’s lead cancer drug makes it to market.

Abstract: The world is facing unavoidable disaster challenges, especially floods in Thailand, these inundations have been becoming increasingly difficult to manage each year. Therefore, a preliminary ...